Share
Journal Information
Issue
Vol. 16. Issue 3.Pages 176-318 (May - June 2017)
Editorial
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant
Carmen Vinaixa, Marina Berenguer
Ann Hepatol. 2017;16:322-3
Open access
Prospective Indian Study of DILI with Confirmed Causality Using the Roussel Uclaf Causality Assessment Method (RUCAM): A Report of Excellence
Rolf Teschke, Gaby Danan
Ann Hepatol. 2017;16:324-5
Open access
Liver Transplantation as Cure of Hepatocellular Carcinoma: It is not a Matter of Time, it is a Matter of Tumor Biology
Christoph Jochum, Ali Canbay
Ann Hepatol. 2017;16:326-7
Open access
Opinions
The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
Paulina Chinchilla-López, Xingshun Qi, Eric M. Yoshida, Nahum Méndez-Sánchez
Ann Hepatol. 2017;16:328-30
Open access
Viewpoint
MRE in NAFLD: Promising but Further Validation is Required
John D. Ryan, Emmanuel A. Tsochatzis
Ann Hepatol. 2017;16:331-2
Open access
Concise review
What is Changing in Indications and Treatment of Focal Nodular Hyperplasia of the Liver. Is There any Place for Surgery?
Aristotelis Perrakis, Nikolaos Vassos, Robert Grützmann, Roland S. Croner
Ann Hepatol. 2017;16:333-41
Open access
Original article
The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection
Pegah Golabi, Munkhzul Otgonsuren, Mehmet Sayiner, Aimal Arsalla, Trevor Gogoll, Zobair M. Younossi
Ann Hepatol. 2017;16:342-8
Open access
Transient Elastography vs. Aspartate Aminotransferase to Platelet Ratio Index in Hepatitis C: A Meta-Analysis
Ângelo Zambam de Mattos, Angelo Alves de Mattos
Ann Hepatol. 2017;16:349-57
Open access
Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B
Itziar Oyagüez, María Buti, Max Brosa, Magdalena Rueda, Miguel A. Casado
Ann Hepatol. 2017;16:358-65
Open access
Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
Jacob A. Langness, David Tabano, Amanda Wieland, Sarah Tise, Lindsay Pratt, Lauren Ayres Harrington, Sonia Lin, Vahram Ghuschcyan, ... Gregory T. Everson
Ann Hepatol. 2017;16:366-74
Open access
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant
Eric M. Yoshida, Paul Kwo, Kosh Agarwal, Christophe Duvoux, François Durand, Markus Peck-Radosavljevic, Leslie Lilly, Bernard Willems, ... Beat Müllhaupt
Ann Hepatol. 2017;16:375-81
Open access
Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Veeravich Jaruvongvanich, Anawin Sanguankeo, Tanawan Riangwiwat, Sikarin Upala
Ann Hepatol. 2017;16:382-94
Open access
The Utilization of Palliative Care Services in Patients with Cirrhosis who have been Denied Liver Transplantation: A Single Center Retrospective Review
Sean G. Kelly, Toby C. Campbell, Luke Hillman, Adnan Said, Michael R. Lucey, Parul D. Agarwal
Ann Hepatol. 2017;16:395-401
Open access
Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center
William C. Palmer, David Lee, Justin Burns, Kristopher Croome, Barry Rosser, Tushar Patel, Andrew P. Keaveny, Surakit Pungpapong, ... Denise M. Harnois
Ann Hepatol. 2017;16:402-11
Open access
Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load
Li-Shuai Qu, Jin-Xia Liu, Jing Zhu, Cui-Hua Lu
Ann Hepatol. 2017;16:412-20
Open access
Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis
Roongruedee Chaiteerakij, Piyanat Chattieng, Jonggi Choi, Nutcha Pinchareon, Kessirin Thanapirom, Nopavut Geratikornsupuk
Ann Hepatol. 2017;16:421-9
Open access
Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability
Yazmín Karel Melchor-Mendoza, Braulio Martínez-Benítez, Aline Mina-Hawat, Gustavo Rodríguez-Leal, Ximena Duque, Segundo Moran-Villota
Ann Hepatol. 2017;16:430-5
Open access
Cholangiohydatidosis: an Infrequent Cause of Obstructive Jaundice and Acute Cholangitis
Carlos Manterola, Tamara Otzen
Ann Hepatol. 2017;16:436-41
Open access
Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality
Chetan Rathi, Nirav Pipaliya, Ruchir Patel, Meghraj Ingle, Aniruddha Phadke, Prabha Sawant
Ann Hepatol. 2017;16:442-50
Open access
GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors
Federico Greni, Luca Valenti, Raffaella Mariani, Irene Pelloni, Raffaela Rametta, Fabiana Busti, Giulia Ravasi, Domenico Girelli, ... Sara Pelucchi
Ann Hepatol. 2017;16:451-6
Open access
Images in hepatology
Spontaneous Resolution of Multiple Hepatic Masses: Hepatic Inflammatory Pseuduotumor
Xingshun Qi, Lei Han, Ankur Arora, Yue Hou, Ran Wang, Sha Chang, Xiaozhong Guo
Ann Hepatol. 2017;16:457-9
Open access
Case report
Recurrent Hyperammonemia After Abernethy Malformation Type 2 Closure: a Case Report
Hui Li, Zhi Ma, Ying Xie, Feng Tian
Ann Hepatol. 2017;16:460-4
Open access
A Rare BSEP Mutation Associated with a Mild Form of Progressive Familial Intrahepatic Cholestasis Type 2
Orith Waisbourd-Zinman, Lea F. Surrey, Anna E. Schwartz, Pierre A. Russo, Jessica Wen
Ann Hepatol. 2017;16:465-8
Open access
Correspondence
HbA1c Levels as a Parameter of Glycemic Control in Patients with Liver Diseases
Leonardo de Lucca Schiavon, Janaína Luz Narciso-Schiavon
Ann Hepatol. 2017;16:469-70
Open access
Correspondence (reply)
Reply to “HbA1c Levels as a Parameter of Glycemic Control in Patients with Liver Cirrhosis”
Jonathan G. Stine, Javelle A. Wynter, Blake Niccum, Virginia Kelly, Stephen H. Caldwell, Neeral L. Shah
Ann Hepatol. 2017;16:471-2
Open access
Publish in
Annals of Hepatology
Special content about COVID-19
- Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study
- Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells
- P-2 NASH IS IMPROVED THROUGH MODIFICATIONS IN H3K9 METHYLATION BY PIRFENIDONE ACTING AS JMJD2B DEMETHYLASE ANTAGONIST.
- O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
Affiliated societies
